HEM dysplasia

HEM Dysplasia: A Comprehensive Medical Review

Introduction

HEM dysplasia, also known as Greenberg dysplasia or Hydrops-Ectopic calcification-Moth-eaten skeletal dysplasia, is an extremely rare autosomal recessive skeletal disorder first described by Greenberg and colleagues in 1988. According to trusted medical organizations including Orphanet, the National Organization for Rare Disorders (NORD), and the National Institutes of Health (NIH), this condition is characterized by the triad of fetal Hydrops, Ectopic calcification, and Moth-eaten skeletal appearance. The syndrome represents one of the most severe forms of skeletal dysplasia, with uniformly lethal outcomes during the prenatal or perinatal period, making it a devastating condition for affected families.^{[1][2][3][4][5]}

Definition and Classification

Disease Definition

According to Orphanet, the European reference portal for rare diseases, Greenberg dysplasia (HEM dysplasia) is defined as “a very rare lethal skeletal dysplasia characterized by fetal hydrops, short limbs and abnormal chondro-osseous calcification”. The condition is classified under multiple medical taxonomies:^[5]

• OMIM Classification: #215140 (Greenberg skeletal dysplasia)
• Orphanet Code: ORPHA:1426
• MIM: 215140

Synonyms and Nomenclature

The condition is known by several names in medical literature:^[2][4][5]

• HEM dysplasia (Hydrops-Ectopic calcification-Moth-eaten dysplasia)
• Greenberg dysplasia
• Greenberg skeletal dysplasia
• Hydrops-ectopic calcification-moth-eaten skeletal dysplasia
• Skeletal dysplasia, Greenberg type

Epidemiology and Demographics

Prevalence and Geographic Distribution

HEM dysplasia is considered one of the rarest genetic skeletal disorders:

Global Prevalence: According to Orphanet and recent literature reviews, the prevalence is estimated at less than 1 per 1,000,000 individuals worldwide.^[5]

Documented Cases: Fewer than ten cases have been published in the medical literature since the syndrome’s initial description in 1988. By 2020, approximately eleven well-documented cases had been reported in various publications.^[6][7][5]

Geographic Distribution: Cases have been reported globally without specific ethnic or geographic clustering, affecting families of diverse backgrounds including Turkish, East-Indian, and Chinese populations.^[7][1][2]

Demographic Characteristics

Age at Presentation: The condition is invariably fatal during the prenatal or early neonatal period:^[5]

• Prenatal detection: Usually detected during routine fetal ultrasound between 17-25 weeks of gestation^[2][7]
• Intrauterine death: Most cases result in fetal death before 20 weeks gestation
• Perinatal lethality: No affected individuals survive beyond the neonatal period

Gender Distribution: The condition affects both males and females equally, consistent with its autosomal recessive inheritance pattern.^[1][2]

Family History: Given the autosomal recessive inheritance, affected individuals typically have unaffected parents who are carriers, with consanguinity increasing the risk significantly.^[7][1][2]

Pathophysiology and Molecular Mechanisms

Genetic Basis

LBR Gene Mutations: HEM dysplasia is caused by biallelic pathogenic variants in the LBR (Lamin B Receptor) gene located on chromosome 1q42.12. The LBR gene encodes a bifunctional protein that serves as both an inner nuclear membrane protein and a sterol reductase enzyme.^[8][6][1]

Molecular Function: The lamin B receptor protein has two distinct functional domains:^[6][1]

• Nuclear structural domain: Involved in nuclear organization and chromatin structure
• Sterol reductase domain: Essential for cholesterol biosynthesis, specifically catalyzing the reduction of cholesta-8,14-dien-3β-ol to cholesta-8-en-3β-ol

Pathophysiological Mechanisms

Cholesterol Biosynthesis Defect: The primary pathogenetic mechanism involves disruption of cholesterol biosynthesis:^[3][1]

• 3β-hydroxysterol Δ14-reductase deficiency: Loss of enzymatic activity leads to accumulation of cholesta-8,14-dien-3β-ol
• Sterol intermediate accumulation: Elevated levels of abnormal sterol intermediates in tissues and cells
• Developmental consequences: Disrupted cholesterol metabolism affects multiple developmental processes

Developmental Impact: Cholesterol is essential for normal embryonic development, particularly:^[4][3]

• Cell membrane integrity: Required for proper cellular structure and function
• Signaling pathways: Critical for hedgehog and other developmental signaling cascades
• Organogenesis: Essential for proper organ system development
• Skeletal development: Particularly important for cartilage and bone formation

Allelic Spectrum

Related Conditions: Mutations in the LBR gene cause a spectrum of disorders:^[1][6]

• Greenberg dysplasia (HEM): Most severe, lethal form with biallelic loss-of-function mutations
• Pelger-Huët anomaly (PHA): Benign dominant condition with nuclear morphology defects
• PHASK syndrome: Pelger-Huët anomaly with mild skeletal abnormalities
• Intermediate phenotypes: Range from mild to moderate skeletal dysplasia^[7]

Clinical Manifestations

The HEM Triad

The syndrome’s acronym reflects its three cardinal features, each representing severe developmental abnormalities:^[9][4][2]

H – Hydrops Fetalis

Clinical Characteristics:^[2][5]

• Universal finding: Present in virtually all reported cases
• Generalized edema: Extensive fluid accumulation throughout fetal tissues
• Severity: Often severe enough to be detected on routine prenatal ultrasound
• Associated findings: May include polyhydramnios, cystic hygroma
• Pathophysiology: Related to cardiovascular dysfunction and altered vascular permeability

E – Ectopic Calcification

Abnormal Calcium Deposits:^[9][2][5]

• Location: Inappropriate calcification in soft tissues and cartilage
• Distribution: Affects ribs, sternum, pelvis, and epiphyses
• Appearance: Creates characteristic radiographic abnormalities
• Mechanism: Disrupted calcium-phosphate homeostasis due to metabolic abnormalities
• Consequences: Contributes to skeletal malformation and dysfunction

M – Moth-eaten Skeletal Appearance

Distinctive Radiographic Pattern:^[9][2][5]

• Long bones: Characteristic spotted, irregular appearance on X-rays
• Universal finding: Present in all documented cases
• Severity: Affects all tubular bones with varying degrees of involvement
• Associated features: Combined with severe shortening and deformity
• Pathognomonic sign: Virtually diagnostic when present with other features

Associated Clinical Features

Skeletal Abnormalities

Severe Skeletal Dysplasia:^[4][2][5]

• Short-limbed dwarfism: Extreme shortening of all long bones
• Platyspondyly: Flattened, abnormally shaped vertebrae
• Rib abnormalities: Short, irregular ribs with calcification
• Pelvic dysplasia: Abnormal pelvic bone development and calcification
• Joint malformation: Defective or absent joint formation

Additional Skeletal Features:^[2][5]

• Polydactyly: Extra digits, particularly postaxial polydactyly
• Brachydactyly: Shortened fingers and toes
• Abnormal ossification: Disrupted endochondral ossification
• Multiple ossification centers: Aberrant bone formation patterns

Systemic Abnormalities

Cardiovascular Features:^[2]

• Cardiomegaly: Enlarged heart contributing to hydrops
• Heart failure: Congestive heart failure in some cases
• Vascular abnormalities: Altered vascular development

Pulmonary Abnormalities:^[5]

• Pulmonary hypoplasia: Underdeveloped lungs
• Incomplete lung lobation: Abnormal lung structure
• Respiratory insufficiency: Contributing to perinatal mortality

Additional Features:^[5][2]

• Facial dysmorphism: Unusual facial features in some cases
• Cystic hygroma: Fluid-filled sacs in neck region
• Intestinal malrotation: Abnormal bowel positioning
• Extramedullary hematopoiesis: Abnormal blood cell production sites

Diagnostic Approach

Prenatal Diagnosis

Ultrasound Findings

First-Line Detection:^[10][7][2]

• Gestational age: Usually detected between 17-25 weeks gestation
• Key findings: Severe hydrops fetalis, short-limbed dwarfism
• Associated findings: Polyhydramnios, cystic hygroma
• Skeletal abnormalities: Severely shortened and deformed long bones
• Thoracic abnormalities: Small chest cavity, rib deformities

Ultrasound Limitations:^[7]

• Cannot definitively distinguish from other lethal skeletal dysplasias
• May miss subtle early changes
• Requires experienced sonographer for accurate assessment

Radiological Assessment

Fetal Radiography:^[9][2]

• Moth-eaten appearance: Pathognomonic finding in long bones
• Platyspondyly: Flattened vertebrae with multiple ossification centers
• Ectopic calcification: Abnormal calcium deposits in ribs, sternum, pelvis
• Deficient skull ossification: Poor cranial bone formation
• Overall pattern: Distinctive combination of findings

Genetic Testing

Molecular Diagnosis

LBR Gene Analysis:^[8][6][7]

• Whole exome sequencing: Comprehensive genetic analysis
• Targeted gene sequencing: Focus on LBR gene coding regions
• Biallelic mutations: Identification of compound heterozygous or homozygous variants
• Functional validation: Assessment of sterol reductase activity when indicated

Recent Genetic Findings:^[7]

• Novel mutations continue to be identified
• Genotype-phenotype correlations being established
• Intermediate phenotypes with milder presentations
• Importance of variant pathogenicity assessment

Biochemical Testing

Sterol Analysis:^[4][1]

• Elevated cholesta-8,14-dien-3β-ol: Pathognomonic biochemical finding
• Cultured fibroblasts: Preferred tissue for sterol analysis
• Prenatal diagnosis: Possible using amniotic fluid or chorionic villus sampling
• Carrier detection: May be possible through biochemical analysis

Differential Diagnosis

Primary Considerations

Thanatophoric Dysplasia:^[2]

• Similarities: Severe short-limbed dwarfism, hydrops
• Differences: Different radiographic pattern, no moth-eaten appearance
• Genetic basis: FGFR3 mutations vs. LBR mutations

Other Lethal Skeletal Dysplasias:^[5]

• Achondrogenesis: Different pattern of skeletal involvement
• Osteogenesis imperfecta type II: Fractures, different bone texture
• Campomelic dysplasia: Sex reversal, different skeletal pattern

Secondary Considerations

TORCH Infections:^[2]

• May cause hydrops and growth restriction
• Different pattern of abnormalities
• Infectious etiology vs. genetic cause

Chromosomal Abnormalities:

• Various trisomies can cause multiple anomalies
• Karyotype analysis helps exclude these conditions

Treatment and Management

Current Approach

Given the invariably lethal nature of HEM dysplasia, management focuses on supportive care and family counseling:^[5]

Prenatal Management

Pregnancy Counseling:^[11][7]

• Prognosis discussion: Frank discussion of uniformly lethal prognosis
• Delivery planning: Consideration of comfort care measures
• Family support: Psychological support throughout pregnancy
• Decision making: Support for difficult reproductive choices

Supportive Care

Comfort Measures:

• Pain management: Appropriate analgesics when indicated
• Respiratory support: Limited interventions given prognosis
• Family involvement: Maximizing family time and bonding
• Palliative approach: Focus on comfort rather than aggressive intervention

Genetic Counseling

Recurrence Risk Assessment

Autosomal Recessive Inheritance:^[1][7]

• Parental carrier status: Both parents are obligate carriers
• Recurrence risk: 25% risk for each subsequent pregnancy
• Carrier testing: Available for extended family members
• Population screening: May be considered in high-risk populations

Reproductive Options

Future Pregnancies:^[11][7]

• Prenatal diagnosis: Available through molecular and biochemical testing
• Preimplantation genetic diagnosis: Option for affected families
• Early detection: Allows for informed decision-making
• Family planning: Comprehensive counseling about reproductive choices

Prognosis and Natural History

Disease Course

Uniformly Lethal Prognosis: HEM dysplasia has a 100% mortality rate with no survivors reported beyond the neonatal period:^[5]

Prenatal Period:^[7][2]

• Early detection: Usually identified in second trimester
• Intrauterine death: Common outcome before 20 weeks gestation
• Fetal compromise: Progressive deterioration throughout pregnancy

Perinatal Period:^[2]

• Live birth: Rare, when it occurs infants are severely affected
• Respiratory failure: Primary cause of death when born alive
• Multi-organ failure: Multiple system involvement contributes to mortality

Factors Affecting Outcome

Uniformly Poor Prognosis: No favorable prognostic factors have been identified:

• Severity of mutations: All reported mutations result in significant enzyme deficiency
• Completeness of syndrome: All cases show multiple system involvement
• Lack of treatment: No effective therapies currently available

Research and Future Directions

Current Research Areas

Pathophysiology Studies:^[6][1]

• Cholesterol metabolism: Understanding role in embryonic development
• Animal models: Development of mouse models for mechanistic studies
• Cellular studies: Investigation of cellular consequences of LBR deficiency
• Developmental biology: Role of cholesterol in organogenesis

Clinical Research:^[7]

• Genotype-phenotype correlations: Relating mutations to clinical severity
• Phenotype expansion: Recognition of milder presentations
• Natural history studies: Better characterization of disease course
• Prenatal diagnosis: Improving early detection methods

Emerging Technologies

Therapeutic Development:

• Cholesterol supplementation: Theoretical approaches to bypass metabolic block
• Gene therapy: Long-term research goals for genetic correction
• Pharmacological interventions: Drugs targeting cholesterol metabolism
• Precision medicine: Mutation-specific treatment approaches

Diagnostic Advances:

• Improved genetic testing: Better mutation detection methods
• Functional assays: Assessment of enzymatic activity
• Biomarker discovery: Non-invasive diagnostic indicators
• Prenatal screening: Enhanced early detection capabilities

Global Health Perspectives

Healthcare Access and Challenges

Developed Countries:

• Specialized centers: Access to genetic counseling and testing
• Advanced imaging: Detailed prenatal diagnosis capabilities
• Palliative care: Comprehensive end-of-life support
• Research participation: Opportunities for advancing knowledge

Resource-Limited Settings:

• Diagnostic challenges: Limited genetic testing availability
• Basic prenatal care: Focus on routine obstetric management
• Family support: Community-based counseling approaches
• Prevention strategies: Genetic education and counseling

Public Health Implications

Rare Disease Awareness:

• Healthcare provider education: Recognition of skeletal dysplasias
• Genetic counseling: Training in recessive inheritance patterns
• Research infrastructure: Support for rare disease studies
• International collaboration: Sharing of expertise and resources

Ethical Considerations

Prenatal Testing and Decision Making

Reproductive Autonomy:

• Informed consent: Comprehensive counseling about testing implications
• Decision support: Non-directive counseling approaches
• Cultural considerations: Respecting diverse perspectives on pregnancy decisions
• Family dynamics: Supporting difficult family decisions

Research Ethics

Rare Disease Research:

• Tissue banking: Ethical collection and storage of samples
• International collaboration: Sharing of clinical and genetic data
• Benefit sharing: Ensuring research benefits affected communities
• Privacy protection: Safeguarding genetic information

Recent Case Reports and Clinical Insights

Novel Genetic Discoveries

Expanding Mutation Spectrum:^[7]

• Novel variants: c.1757G>A (p.Arg586His) in Chinese families
• Intermediate phenotypes: Milder presentations with longer survival
• Genotype-phenotype correlations: Different mutations causing variable severity
• Functional validation: Importance of assessing variant pathogenicity

Prenatal Diagnosis Advances

Improved Detection Methods:^[7]

• Whole exome sequencing: Enhanced diagnostic capabilities
• Earlier detection: Recognition of milder phenotypes
• Family screening: Identification of at-risk pregnancies
• International experience: Cases reported from diverse populations

Conclusion

HEM dysplasia (Greenberg dysplasia) represents one of the most severe and uniformly lethal genetic skeletal disorders affecting human development. This rare autosomal recessive condition, caused by mutations in the LBR gene encoding the lamin B receptor, exemplifies the critical importance of cholesterol metabolism in embryonic development and demonstrates how disruption of a single biochemical pathway can result in catastrophic multi-system abnormalities.

The syndrome’s pathophysiology, rooted in defective cholesterol biosynthesis due to 3β-hydroxysterol Δ14-reductase deficiency, provides crucial insights into the role of sterol metabolism in skeletal development, cardiovascular function, and overall embryogenesis. The accumulation of cholesta-8,14-dien-3β-ol and other abnormal sterol intermediates disrupts normal developmental processes, resulting in the characteristic triad of hydrops fetalis, ectopic calcification, and moth-eaten skeletal appearance that defines this devastating condition.

From a clinical perspective, HEM dysplasia presents unique challenges for healthcare providers, geneticists, and families. The invariably lethal prognosis, with no survivors beyond the neonatal period, necessitates sensitive counseling and comprehensive support throughout the diagnostic and management process. The distinctive radiographic findings, particularly the pathognomonic moth-eaten appearance of long bones, provide important diagnostic clues that can help differentiate this condition from other lethal skeletal dysplasias.

The diagnostic approach has evolved significantly with advances in genetic testing technologies. Whole exome sequencing has revolutionized the ability to confirm the diagnosis and identify novel mutations, while biochemical analysis of sterol intermediates provides functional confirmation of the enzymatic defect. These advances have also enabled better understanding of the phenotypic spectrum associated with LBR mutations, ranging from the lethal Greenberg dysplasia to the benign Pelger-Huët anomaly.

The genetic counseling implications of HEM dysplasia are particularly significant given its autosomal recessive inheritance pattern and the 25% recurrence risk for subsequent pregnancies in carrier couples. The availability of prenatal diagnosis through both biochemical and molecular methods provides reproductive options for affected families, though these decisions involve complex ethical and emotional considerations given the uniformly poor prognosis.

Recent research has expanded our understanding of the phenotypic spectrum associated with LBR mutations, with reports of intermediate phenotypes presenting milder skeletal dysplasia and longer survival than classical Greenberg dysplasia. These findings suggest that the relationship between genotype and phenotype may be more complex than initially recognized, opening avenues for better prognostic assessment and potentially targeted therapeutic approaches.

The study of HEM dysplasia has also contributed significantly to our broader understanding of cholesterol metabolism and its role in human development. The identification of this condition as part of the growing family of disorders involving defects in postsqualene cholesterol biosynthesis has enhanced our appreciation of the critical importance of sterol metabolism in embryogenesis and development.

Looking toward the future, several research directions hold promise for advancing knowledge about HEM dysplasia and related conditions. The development of appropriate animal models could provide platforms for studying disease mechanisms and testing potential therapeutic interventions. While current treatment options are limited to supportive care, understanding the molecular basis of the condition opens theoretical possibilities for cholesterol supplementation, enzyme replacement, or gene therapy approaches.

The international collaboration facilitated by modern communication and genetic databases has been essential for advancing knowledge about this ultra-rare condition. The sharing of clinical data, genetic findings, and biological samples across institutions and countries has enabled the identification of novel mutations and the characterization of phenotypic variants that might otherwise have remained unrecognized.

Healthcare providers should maintain awareness of HEM dysplasia as a potential diagnosis in pregnancies complicated by severe fetal hydrops, short-limbed dwarfism, and characteristic skeletal abnormalities detected on prenatal imaging. Early recognition allows for appropriate genetic testing, family counseling, and decision-making support during these difficult circumstances.

The syndrome also serves as an important model for understanding the challenges and opportunities in rare disease research. The limited number of cases makes traditional clinical studies difficult, but the availability of modern genetic and biochemical analytical tools provides unprecedented opportunities to understand disease mechanisms and identify potential therapeutic targets.

As our understanding of cholesterol metabolism and its role in human development continues to evolve, HEM dysplasia will likely continue to provide important insights into these fundamental biological processes. The lessons learned from studying this rare but devastating condition contribute not only to improved care for affected families but also to broader understanding of developmental biology, genetic disease mechanisms, and the complex relationships between metabolism and embryogenesis.

The story of HEM dysplasia ultimately illustrates both the challenges and the potential rewards of investigating rare genetic disorders. While the condition itself remains uniformly lethal, the knowledge gained from its study has enhanced our understanding of human development and may eventually contribute to therapeutic approaches for this and related conditions. The syndrome serves as a poignant reminder of the importance of continued investment in rare disease research and the value of international collaboration in advancing medical knowledge and improving patient care.

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC1180330/          
2. https://pubmed.ncbi.nlm.nih.gov/8213919/                   
3. https://medlineplus.gov/genetics/condition/greenberg-dysplasia/  
4. https://www.malacards.org/card/greenberg_dysplasia     
5. https://www.orpha.net/en/disease/detail/1426               
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7284023/     
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9883016/               
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6349533/ 
9. https://en.wikipedia.org/wiki/Hydrops-ectopic_calcification-moth-eaten_skeletal_dysplasia   
10. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pd.2676
11. https://pubmed.ncbi.nlm.nih.gov/2077906 
12. https://rarediseases.org/mondo-disease/greenberg-dysplasia/
13. https://rarediseases.org/rare-diseases/recessive-multiple-epiphyseal-dysplasia/
14. https://en.wikipedia.org/wiki/Multiple_epiphyseal_dysplasia
15. https://medlineplus.gov/genetics/condition/multiple-epiphyseal-dysplasia/
16. https://www.orthobullets.com/pediatrics/4095/multiple-epiphyseal-dysplasia-med
17. https://onlinelibrary.wiley.com/doi/full/10.1002/mgg3.1173
18. https://kidshealth.org/en/parents/multiple-epiphyseal-dysplasia.html
19. https://medlineplus.gov/download/genetics/condition/greenberg-dysplasia.pdf
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC4063216/
21. https://www.cancer.org.au/assets/pdf/myelodysplastic-syndrome-quick-reference-guide
22. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1522644/full
23. https://www.sciencedirect.com/science/article/abs/pii/S0009898120301868
24. https://www.rarediseaseadvisor.com/insights/role-supportive-care-myelodysplastic-yndromes/
25. https://pubmed.ncbi.nlm.nih.gov/37195773/
26. https://emedicine.medscape.com/article/207347-overview
27. https://emedicine.medscape.com/article/207347-treatment
28. https://www.ncbi.nlm.nih.gov/books/NBK66015/
29. https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/MSS_Myelodysplastic_Syndrome_MDS.pdf
30. https://emedicine.medscape.com/article/207347-guidelines
31. https://www.sciencedirect.com/science/article/pii/S0301472X07000252
32. http://mauriciolema.webhost4life.com/hematooncologiapapers/7HITMDS.pdf